Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

P2 Science, Inc.

Birstol-myers Squibb Company

Yong Tu

Piyasena Hewawasam

John F Kadow

John A Bender

Kap-Sun Yeung

Robert G Gentles

Makonen Belema

Omar D Lopez

Katharine A Grant-Young

Alan Xiangdong Wang

Ying Han

Nicholas A Meanwell

Thomas W Hudyma

Min Ding

Xiaofan Zheng

Zhong Yang

Ningning Xu

Samayamunthula Venkata Satya Arun Kumar Gupta

Paul Michael Scola

Patrick Foley

Andrew Charles Good

B Narasimhulu Naidu

Jeffrey Allen Campbell

Yonghua Yang

Alicia Regueiro-Ren

Mark George Saulnier

Ashoke Bhattacharjee

Gan Wang

Van N Nguyen

Manoj Patel

Prasanna Sivaprakasam

Kyle E Parcella

Scott W Martin

Stanley V D'Andrea

David Bertil Frennesson

Kyle J Eastman

Carl P Bergstrom

Min Gao

Hasibur Rahaman

Jianqing Li

Fiona McPhee

Julie A Lemm

Ying-Kai Wang

Pothukanuri Srinivasu

Robert A Fridell

Jin-Hua Sun

Donald R O'Boyle, Ii

Amy Ripka

Chunfu Wang

Roshan Yadavrao Nimje

Ponugupati Suresh Kumar

Indasi Gopi Kumar

Suresh Kumar Ponugupati

Indasi J Gopi Kumar

Suresh Kumar Punugupati

Donald R O'BOYLE Ii

Piyasena Hewasam

The present disclosure pertains to a new synthetic method for the preparation of 2-methyl-2-hydroxyheptane and 2-methyl-2-alkoxyheptanes, which are valuable commodities for use in flavors, fragrances and various personal care products, such as cosmetics.

Method for synthesis of 2-methyl-2-hydroxyheptane and 2-methyl 2-alkoxyheptanes

The present disclosure pertains to new methods of performing a hydrodealkenylation of monounsaturated alcohols, thiols, and derivatives thereof, such as terpenes and derivatives, comprising ozonolysis and quenching using a sulfinic acid or sulfinic acid salt.

Methods for hydrodealkenylation

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV. 

Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. 

Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. 

Compounds for the treatment of Hepatitis C

The invention encompasses compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the treatment of hepatitis C

The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. 

The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. 

Indolobenzazepine HCV NS5B inhibitors

Growing community of inventors

Cheshire, CT, United States of America

Yong Tu